Enzalutamide helps extend life for men with advanced prostate cancer, five-year follow-up finds

by

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to a five-year follow-up of the global ARCHES study led by the Duke Cancer Institute.

Leave A Comment

Your email address will not be published. Required fields are marked *